Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sd-rxRNA COX2
- Development stage
- Preclinical
- Lead developer
- Phio Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal, Intratumoral
01
Overview
sd-rxRNA COX2 is a preclinical RNA interference (RNAi) therapeutic developed by Phio Pharmaceuticals (formerly RXi Pharmaceuticals) using its proprietary self-delivering rxRNA (sd-rxRNA) platform. The compound is designed to silence the PTGS2 gene, which encodes cyclooxygenase-2 (COX-2), a key enzyme in the production of pro-inflammatory prostaglandins. Unlike traditional siRNA, sd-rxRNA molecules are chemically modified to enable spontaneous cellular uptake without the need for delivery vehicles or electroporation. The molecule features a unique asymmetric structure with phosphorothioate modifications and high chemical stabilization. It has been explored for the treatment of proliferative vitreoretinopathy (PVR) via intravitreal administration and as an immunomodulatory agent to reduce immunosuppression in the tumor microenvironment (TME) by targeting myeloid-derived suppressor cells (MDSCs).
- Other names
- sd-rxRNA targeting COX2sd-rxRNA targeting PTGS2self-delivering rxRNA targeting COX2
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on sd-rxRNA COX2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sd-rxRNA COX2.